

Applicants: Yuan Chang, et al.
Serial No.: 09/607,179
Filed : June 29, 2000
Page 7

B13
CONT.

under optimal conditions. Sample preparations were prealiquoted and amplified with alternating negative control samples without DNA to monitor and control possible contamination. All samples were tested in a blinded fashion and a determination of the positivity/negativity made before code breaking. Significance testing was performed with Mantel-Haenszel chi-squared estimates and exact confidence intervals using Epi-Info ver. 6 (USD Inc., Stone Mt.GA).

✓
Please replace the previously submitted Sequence Listing with the Sequence Listing attached hereto as Exhibit C.

✓
Please also replace pages 27, 91, 92 and 134 of the specification with replacement pages 27, 91, 92 and 134 attached hereto as Exhibit F.

In the claims:

✓
Please cancel claims 43 and 49 without prejudice to applicants' right to pursue the subject matter of these claims in a continuing application.

Please add new claims 50 and 51 as follows:

B14

50. (New) An isolated peptide encoded by a nucleic acid which (i) is at least 30 nucleotides in length and (ii) has a nucleotide sequence which uniquely defines a herpesvirus associated with Kaposi's sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762). C

51. (New) A composition which comprises the peptide of claim 50
